News & Updates

Show Multimedia Only

With the emergence of new subtypes of respiratory nosocomial infection and multi-drug resistant organisms (MDROs), better surveillance and infection prevention and control are necessary to address these healthcare challenges.

18 Jan 2024 by

With the emergence of new subtypes of respiratory nosocomial infection and multi-drug resistant organisms (MDROs), better surveillance and infection prevention and control are necessary to address these healthcare challenges. In the MSD-sponsored scientific event entitled “Multidrug Resistant Infections: Updates on Diagnosis and Management” held on July 27, 2023, Dr Evelina Lagamayo, Clinical Pathologist and Microbiologist, Section Chief, Microbiology Department of Clinical Pathology, University of Santo Tomas Hospital; Dr Rontgene Solante, Chair, Adult Infectious Disease, Tropical Medicine, San Lazaro Hospital, and President of the Philippine College of Physicians; and Dr Carmenchu Villavicencio, Infection Control Chair of St. Luke’s Medicla Center Global City, as moderator discussed diagnostic tests for Enterobacterales and Pseudomonas aeruginosa, and the role of ceftolozane/tazobactam (ZERBAXA) in the treatment nosocomial pneumonia.

With the emergence of new subtypes of respiratory nosocomial infection and multi-drug resistant organisms (MDROs), better surveillance and infection prevention and control are necessary to address these healthcare challenges.

18 Jan 2024

Inhaled amikacin cuts VAP burden in mechanically ventilated patients

16 Jan 2024 by

In critically ill patients who have been on invasive mechanical ventilation (IMV) for at least 3 days, a subsequent 3-day course of preventive inhaled amikacin reduced the burden of ventilator-associated pneumonia (VAP) during 28 days of follow-up, findings from the AMIKINHAL trial have shown.

Inhaled amikacin cuts VAP burden in mechanically ventilated patients

16 Jan 2024

Shorter antibiotic regimen just as effective for febrile urinary tract infection in children

15 Jan 2024

A 5-day course of oral amoxicillin-clavulanate performs just as wells as a 10-day course in the treatment of febrile urinary tract infection (fUTI) in children, a study has shown.

Shorter antibiotic regimen just as effective for febrile urinary tract infection in children

15 Jan 2024

Add-on clarithromycin boosts recovery from pneumonia

13 Jan 2024

Adding clarithromycin to standard of care appears to improve clinical response and reduce inflammation in patients with community-acquired pneumonia, as reported in the phase III ACCESS trial.

Add-on clarithromycin boosts recovery from pneumonia

13 Jan 2024

Linezolid flops against benzathine penicillin G for early syphilis

12 Jan 2024

In the treatment of patients with early syphilis, a 5-day course of linezolid does not appear to perform as well as the standard of care benzathine penicillin G (BPG), as shown in a study.

Linezolid flops against benzathine penicillin G for early syphilis

12 Jan 2024

The future of COVID-19 management: A spotlight on respirology

10 Jan 2024 by

At the 27th Congress of the Asian Pacific Society of Respirology (APSR) 2023, a Pfizer-sponsored symposium addressed the evolving challenges of COVID-19, particularly for patients with pre-existing respiratory conditions. Chaired by Dr Chan Kwok Wai Adrian, a renowned respiratory physician and intensivist from Mount Elizabeth Novena Hospital, Singapore, and featuring insights from Professor Yang Kuang-Yao of National Yang Ming Chiao Tung University, Taipei, Taiwan, the symposium focused on the disease’s impact, treatment guidelines, regional management strategies, and the role of nirmatrelvir/ritonavir, a new oral combination pill, in the treatment of COVID-19.

The future of COVID-19 management: A spotlight on respirology

10 Jan 2024

mRNA boosters protect cancer patients against adverse COVID-19 outcomes

08 Jan 2024 by

A prospective study from Singapore provides evidence of the clinical effectiveness of mRNA-based vaccines against COVID-19 in individuals with cancer.

mRNA boosters protect cancer patients against adverse COVID-19 outcomes

08 Jan 2024

Original New Drug Application Approvals by US FDA (16-31 December 2023)

03 Jan 2024

New drug applications approved by US FDA as of 16-31 December 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 December 2023)

03 Jan 2024

Fluvoxamine of little benefit in mild-to-moderate COVID-19

02 Jan 2024

The use of fluvoxamine for outpatient treatment of mild-to-moderate COVID-19 falls short of reducing the duration of symptoms, as shown in the ACTIV-6 study.

Fluvoxamine of little benefit in mild-to-moderate COVID-19

02 Jan 2024

Severe outcomes more likely with Omicron XBB.1.16 in SG

29 Dec 2023 by

In a preliminary analysis, the risk of severe outcomes was higher in individuals infected with the Omicron XBB.1.16 subvariant compared with those who were infected with other subvariants such as the XBB.1.5 or XBB.1.9.

Severe outcomes more likely with Omicron XBB.1.16 in SG

29 Dec 2023

News & Updates

Filter by Specialty:

Specialty:

With the emergence of new subtypes of respiratory nosocomial infection and multi-drug resistant organisms (MDROs), better surveillance and infection prevention and control are necessary to address these healthcare challenges.

With the emergence of new subtypes of respiratory nosocomial infection and multi-drug resistant organisms (MDROs), better surveillance and infection prevention and control are necessary to address these healthcare challenges.

Inhaled amikacin cuts VAP burden in mechanically ventilated patients

Inhaled amikacin cuts VAP burden in mechanically ventilated patients

Shorter antibiotic regimen just as effective for febrile urinary tract infection in children

Shorter antibiotic regimen just as effective for febrile urinary tract infection in children

Add-on clarithromycin boosts recovery from pneumonia

Add-on clarithromycin boosts recovery from pneumonia

Linezolid flops against benzathine penicillin G for early syphilis

Linezolid flops against benzathine penicillin G for early syphilis

The future of COVID-19 management: A spotlight on respirology

The future of COVID-19 management: A spotlight on respirology

mRNA boosters protect cancer patients against adverse COVID-19 outcomes

mRNA boosters protect cancer patients against adverse COVID-19 outcomes

Original New Drug Application Approvals by US FDA (16-31 December 2023)

Original New Drug Application Approvals by US FDA (16-31 December 2023)

Fluvoxamine of little benefit in mild-to-moderate COVID-19

Fluvoxamine of little benefit in mild-to-moderate COVID-19

Severe outcomes more likely with Omicron XBB.1.16 in SG

Severe outcomes more likely with Omicron XBB.1.16 in SG